The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Ozen, Alaattin ^a   Kocak, Zafer ^a   Sipahi, Tammam ^a   Oz Puyan, Fulya ^a   Cakina, Suat ^a   Saynak, Mert ^a   Ibis, Cem ^a   Karagol, Hakan ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Gastric adenocarcinoma; Her 2 expression; Her 2 gene polymorphism; p21 expression; p21 gene mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P21; CYCLIN DEPENDENT KINASE INHIBITOR 1A; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; SURVIVAL RATE; TUMOR GENE; ADENOCARCINOMA; GENETICS; GENOTYPE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTO ONCOGENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; STOMACH TUMOR;

ADENOCARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE-FREE SURVIVAL; FEMALE; GENES, ERBB-2; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880585642     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0357-y     Document Type: Article

References (26)

1. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-30.
2. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523-9.
3. Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol. 2009;21:381-5.
4. Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Aikou T. p21 expression is a prognostic factor in patients with p53-negative gastric cancer. Cancer Lett. 2000;148:181-8.
5. Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E, Hermannstädter C, Quintanilla-Martinez L, Busch R, Höfler H, Fend F, Luber B. Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer. J Clin Pathol. 2007;60:756-61.
6. Kouraklis G, Katsoulis IE, Theocharis S, Tsourouflis G, Xipolitas N, Glinavou A, Sioka C, Kostakis A. Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma? Dig Dis Sci. 2009;54:1015-20.
7. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y. WAF1/CIP1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res. 1994;54:1169-74.
8. Sheikh MS, Rochefort H, Garcia M. Overexpression of p21/Waf1/Cip1 induced growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene. 1995;11:1487-98.
9. Chen CY, Faller DV. Direction of p21 generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene. 1995;11:1675-83.
10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledges SJ. The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-16.
11. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-25.
12. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994;54:3391-5.
13. Akagi M, Yasui W, Akama Y, Yokozaki H, Tahara H, Haruma K, Kajiyama G, Tahara E. Inhibition of cell growth by transforming growth factor beta 1 is associated with p53-independent induction of p21 in gastric carcinoma cells. Jpn J Cancer Res. 1996;87:377-84.
14. Yasui W, Akama Y, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol. 1996;180:122-8.
15. Xie HL, Su Q, He XS, Liang XO, Zhou JG, Song Y. Expression of p21WAF1 and p53 and polymorphismof p21WAF1gene in gastric carcinoma. World J Gastroenterol. 2004;10:1125-31.
16. Ogawa M, Maeda K, Onoda N, Chung Y-S, Sowa M. Loss of p21 espression correlates with disease progression in gastric carcinoma. Br J Cancer. 1997;75:1617-20.
17. Seo YH, Joo YE, Choi SK, Rew JS, Park CS, Kim SJ. Prognostic significance of p21 and p53 expression in gastric cancer. Korean J Intern Med. 2003;18:98-103.
18. Mizokami K, Kakeji Y, Oda S, Maehara Y. Relationship of hypoxia-inducible factor 1α and p21WAF1/CIP1 expression to cell apoptosis and clinical outcome in patients with gastric cancer. World J Surg Oncol. 2006;4:94-101.
19. Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N, Ito H. Expression of p21, but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer. 1997;79:2067-72.
20. Müller W, Noguchi T, Wirtz HC, Hommel G, Gabbert HE. Expression of cell-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer. J Pathol. 1999;189:186-93.
21. Park YE, Choi KC, Choi YH. p21 expression and mutation in gastric carcinoma: analysis by immunohistochemistry and PCR-SSCP. J Korean Med Sci. 1998;13:507-12.
22. Chariylertsak S, Sugano K, Ohkura H, Mari Y. Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. Tumour Biol. 1994;15:294-303.
23. Yonemura Y, Ninomiya I, Yamaguchi A. Evalution of immünreactivity for c-erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51:1034-8.
24. Yonemura Y, Ninomiya I, Ohoyama S, Kimura H, Yamaguchi A, Fushida S, Kosaka T, Miwa K, Miyazaki I, Endou Y. Expression of c-erbB-2 oncoprotein in gastric carcinoma. İmmünreactivity for c-erbB-2 protein is an indipentent indicatör of poor short-term prognosis in patients with gastric carcinoma. Cancer. 1991;67:2914-8.
25. Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer. 1993;72:2083-8.
26. Satiroglu-Tufan NL, Bir F, Calli-Demirkan N. Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients. World J Gastroenterol. 2006;12:3283-7.